Trial Profile
Phase Ib/II Trial to Evaluate Safety and Efficacy of Oral Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary) ; Immunosuppressants
- Indications Graft-versus-host disease; Transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 18 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 May 2023 Status changed from recruiting to active, no longer recruiting.
- 20 May 2022 Planned End Date changed from 31 Oct 2022 to 31 Dec 2023.